Lv4
408 积分 2024-10-10 加入
Double-negative B cells
1天前
待确认
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
2天前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
2天前
已完结
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study
17天前
已完结
Lung toxicity induced by anti-HER2 antibody – drug conjugates for breast cancer
18天前
已完结
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents A Phase 3 Randomized Clinical Trial
22天前
已完结
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
22天前
已完结
Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT‐18 in Chinese Patients With Systemic Lupus Erythematosus
28天前
已完结
Prediction of human clearance (CL) and volume of distribution (VD)
1个月前
已完结
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
1个月前
已完结
皖公网安备34019202002308
